Arrowhead Pharmaceuticals Inc at H C Wainwright NASH Investor Conference (Virtual) Transcript
Welcome back, everyone, to the 5th Annual H.C. Wainwright NASH Conference. My name is Patrick Trucchio, and I am a senior biotech analyst at H.C. Wainwright. It is my pleasure to introduce our next presenter, James Hamilton, Senior VP of Discovery and Translational Medicine at Arrowhead Pharmaceuticals, a clinical stage biopharmaceutical company developing medicines to treat intractable disease by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes.
Questions & Answers
So just to begin, James, if we could start with an overview of the Arrowhead TRiM platform, where it is today and where it could go in the future and why it could conceivably be an ideal platform to develop a potential therapy for NASH?
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |